IDB 1031

Drug Profile

IDB 1031

Alternative Names: Cyrtominetin

Latest Information Update: 22 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Indena; Inverni della Beffa
  • Class Anti-inflammatories; Expectorants; Small molecules
  • Mechanism of Action Free radical scavengers; Lipid peroxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Respiratory tract disorders

Most Recent Events

  • 30 Aug 1999 Synthélabo and Sanofi have merged to form Sanofi-Synthélabo
  • 09 Sep 1996 Inverni della Beffa is developing IDB 1031 in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top